Partneringdesk Deals and Alliances In Metabolic Diseases

Partneringdesk deals and alliances in metabolic diseases provides an in-depth view of over 670 deals and alliances announced in metabolic diseases between 2001 and 2006, in a clear and accessible PDF format. Reasons to purchase (USPs and key questions answered) Partneringdesk Deals and alliances in metabolic diseases provides a comprehensive summary of the deals and alliances announced in the field between January 2001 and March 2006, and helps in: the assessment of deal-making trends in the last five years identifying active partners tracking competitor activity benchmarking deals Partneringdesk deals and alliances in metabolic diseases brings all the relevant partnering deals into one place, providing a ready reference to deal making in metabolic diseases. Report scope The report contains: fully categorized deal overviews financial information where disclosed company profiles of the top 25 dealmakers in the report specialized indexes by company, development stage, deal type and industry sector. wider coverage of Japanese deals courtesy of JCN Forecasts, projections, market estimates This report provides a series of charts with analyses detailing market trends in metabolic diseases deal making over the period of 2001 to 2006. Methodology This report is derived from data obtained from Pharmalicensing’s Partneringdesk deals and alliances database. The database is updated daily using industry sources.

Additional Information

Who should buy the report This report is essential reading for board and executive management, and individuals in:

• business development
• licensing/partnering
• deal making
• business strategy
• marketing and promotion
• distribution and manufacturing (including contract services).

Companies analyzed/mentioned
Abbott Laboratories
American Diabetes Association (ADA)
Amylin Pharmaceuticals Inc
AstraZeneca
Biovitrum AB
Bristol-Myers Squibb Company
Cholestech
Eli Lilly and Company
Entelos Inc
GlaxoSmithKline
HealtheTech Inc
Illumina
Kyorin Pharmaceutical
Medical House plc, The
Merck & Co Inc
National Institutes of Health
Novartis AG
Novo Nordisk A/S
Nutrition 21
Pfizer Inc
Roche
Sankyo Co Ltd
Sysmex Corporation
Yamanouchi Pharmaceutical Co Ltd
Zen-Bio